News Features Risking COVID-19 for Professional Gain? Spring’s In-Person Meetings in Hindsight Yael L. Maxwell June 16, 2022
News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020